Herrmann, J. B., and Adair, F. E.: Effect of Testosterone Propionate on Carcinoma of Female Breast with Soft Tissue Metastases , J. Clin. Endocrinol. 6:769-775 (
Herrmann, J. B.; Adair, F. E., and Woodward, H. Q.: Use of Testosterone Propionate in Treatment of Advanced Carcinoma of Breast: II. Treatment of Osseous Metastases , Surgery 22: 101-119 (
Current Status of Hormone Therapy of Advanced Mammary Cancer, report of the Council on Pharmacy and Chemistry , J. A. M. A. 146: 471-477 (
Herrmann, J. B.; Kirsten, E., and Krakauer, J. S.: Hypercalcemic Syndrome Associated with Androgenic and Estrogenic Therapy , J. Clin. Endocrinol. 9:1-12 (
Werner, S. C.; Hanger, F. M., and Kritzler, R. A.: Jaundice During Methyl Testosterone Therapy , Am. J. Med. 8:325-331 (
Segaloff, A., and others: Hormonal Therapy in Cancer of Breast: II. Effect of Methylandrostenediol on Clinical Course and Hormonal Excretion , Cancer 5:271-274 (
The Council on Pharmacy and Chemistry of the American Medical Association has adopted the generic designation stanolone, also known as dihydrotestosterone, androstanolone, androstane-17-(β)-ol-3-one, and Neodrol.
Escher, G. C., and others: Newer Steroids in the Treatment of Advanced Mammary Carcinoma, in Symposium on Steroids in Experimental and Clinical Practice , edited by A. White, Philadelphia, Blakiston Company, 1951;, pp. 375-378.
Farrow, J. H., and others: Evaluation of Androstane-17-(β)-ol-3-one in Treatment of Advanced Mammary Carcinoma , Proc. Am. A. Cancer Res. 1:16 (
Escher, G. C., and others: Dihydrotestosterone (Androstanolone) Therapy of Advanced Mammary Carcinoma , read before the American Federation for Clinical Research, Southern Section, New Orleans, Jan. 30, 1953 , to be published.
Herrmann, J. B.: Unpublished data.